Jeffrey P Meyers

Jeffrey P Meyers

UNVERIFIED PROFILE

Are you Jeffrey P Meyers?   Register this Author

Register author
Jeffrey P Meyers

Jeffrey P Meyers

Publications by authors named "Jeffrey P Meyers"

Are you Jeffrey P Meyers?   Register this Author

18Publications

639Reads

30Profile Views

A nomogram for predicting survival and retroperitoneal lymph node dissection treatment in patients with resected testicular germ cell tumors.

J Surg Oncol 2019 Sep 29;120(3):508-517. Epub 2019 May 29.

National Institute of Clinical Research, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jso.25519DOI Listing
September 2019

Development and validation of a model to predict outcomes of colon cancer surveillance.

Cancer Causes Control 2019 Jul 25;30(7):767-778. Epub 2019 May 25.

Case Western Reserve University School of Medicine, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10552-019-01187-xDOI Listing
July 2019

Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048.

J Clin Oncol 2018 Sep 11:JCO2018788620. Epub 2018 Sep 11.

Ethan Basch, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Bryce B. Reeve, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Ethan Basch, Lauren J. Rogak, Mary C. Shaw, Narre Heon, and Martin R. Weiser, Memorial Sloan Kettering Cancer Center, New York, NY; Amylou C. Dueck and Brenda Ginos, Alliance Statistics and Data Center, Mayo Clinic, Scottsdale, AZ; Sandra A. Mitchell, Lori M. Minasian, and Andrea M. Denicoff, National Cancer Institute, Rockville, MD; Jennifer K. Wind, Harvey J. Mamon, and Deborah Schrag, Dana-Farber/Partners CancerCare, Boston, MA; Qian Shi, Garth D. Nelson, and Jeffrey P. Meyers, Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; George J. Chang, University of Texas MD Anderson Cancer Center, Houston, TX; Tatjana Kolevska, Kaiser Permanente Vallejo Medical Center, Vallejo, CA; and Deborah Watkins Bruner, Emory University, Atlanta, GA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.8620DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209091PMC
September 2018

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.

Authors:
Franck Pagès Bernhard Mlecnik Florence Marliot Gabriela Bindea Fang-Shu Ou Carlo Bifulco Alessandro Lugli Inti Zlobec Tilman T Rau Martin D Berger Iris D Nagtegaal Elisa Vink-Börger Arndt Hartmann Carol Geppert Julie Kolwelter Susanne Merkel Robert Grützmann Marc Van den Eynde Anne Jouret-Mourin Alex Kartheuser Daniel Léonard Christophe Remue Julia Y Wang Prashant Bavi Michael H A Roehrl Pamela S Ohashi Linh T Nguyen SeongJun Han Heather L MacGregor Sara Hafezi-Bakhtiari Bradly G Wouters Giuseppe V Masucci Emilia K Andersson Eva Zavadova Michal Vocka Jan Spacek Lubos Petruzelka Bohuslav Konopasek Pavel Dundr Helena Skalova Kristyna Nemejcova Gerardo Botti Fabiana Tatangelo Paolo Delrio Gennaro Ciliberto Michele Maio Luigi Laghi Fabio Grizzi Tessa Fredriksen Bénédicte Buttard Mihaela Angelova Angela Vasaturo Pauline Maby Sarah E Church Helen K Angell Lucie Lafontaine Daniela Bruni Carine El Sissy Nacilla Haicheur Amos Kirilovsky Anne Berger Christine Lagorce Jeffrey P Meyers Christopher Paustian Zipei Feng Carmen Ballesteros-Merino Jeroen Dijkstra Carlijn van de Water Shannon van Lent-van Vliet Nikki Knijn Ana-Maria Mușină Dragos-Viorel Scripcariu Boryana Popivanova Mingli Xu Tomonobu Fujita Shoichi Hazama Nobuaki Suzuki Hiroaki Nagano Kiyotaka Okuno Toshihiko Torigoe Noriyuki Sato Tomohisa Furuhata Ichiro Takemasa Kyogo Itoh Prabhu S Patel Hemangini H Vora Birva Shah Jayendrakumar B Patel Kruti N Rajvik Shashank J Pandya Shilin N Shukla Yili Wang Guanjun Zhang Yutaka Kawakami Francesco M Marincola Paolo A Ascierto Daniel J Sargent Bernard A Fox Jérôme Galon

Lancet 2018 05 10;391(10135):2128-2139. Epub 2018 May 10.

INSERM, Laboratory of Integrative Cancer Immunology, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Sorbonne Universités, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(18)30789-XDOI Listing
May 2018

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.

N Engl J Med 2018 Mar;378(13):1177-1188

From the Divisions of Medical Oncology (A.G.) and Biomedical Statistics and Informatics (Q.S., J.P.M., L.A.R., D.J.S.), Mayo Clinic, Rochester, MN; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Martino-IST, Genoa (A.F. Sobrero), Ospedale Papa Giovanni XXIII, Bergamo (R.L.), and IRCCS Mario Negri Institute for Pharmacological Research, Milan (V.T.) - all in Italy; Karmanos Cancer Institute, Wayne State University, Detroit (A.F. Shields); National Cancer Center Hospital East, Chiba (T. Yoshino), Yokohama City University School of Medicine, Yokohama (T. Yamanaka), and the University of Tokyo, Tokyo (T.W.) - all in Japan; the Institute of Cancer Sciences, University of Glasgow, Glasgow (J.P.), the University of Oxford, Oxford (R.K.), Christie Hospital, Manchester (M.S.), and University Hospital Southampton, Southampton (T.I.) - all in the United Kingdom; Hôpital Européen Georges-Pompidou, Sorbonne Paris Cite/Paris Descartes University (J.T.), and Saint-Antoine Hospital and Sorbonne Universités, Pierre and Marie Curie University-Paris 6 (T.A.), Paris, and Methodology and Quality of Life Unit, INSERM Unité 1098, Besançon (D.V.) - all in France; the Department of Medical Oncology, University Hospital of Heraklion, Faculty of Medicine, University of Crete, Heraklion (J.S.), and Bioclinic Thessaloniki, Thessaloniki (I.B.) - both in Greece; Dana-Farber Cancer Institute, Boston (J.A.M.); and Duke Cancer Institute, Durham, NC (D.N.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1713709DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426127PMC
March 2018

Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods.

J Clin Oncol 2015 Dec 26;33(34):4048-57. Epub 2015 Oct 26.

Ming-Wen An, Vassar College, Poughkeepsie, NY; Yu Han, Novartis Pharmaceuticals, East Hanover NJ; Jeffrey Meyers, Daniel J. Sargent, and Sumithra J. Mandrekar, Mayo Clinic, Rochester, MN; and Jan Bogaerts, European Organisation for Research and Treatment of Cancer, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.60.8778DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669590PMC
December 2015

A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321.

J Thorac Oncol 2015 Jan;10(1):172-80

*Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY; †Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; ‡Illinois CancerCare, Peoria, IL; §Hematology/Oncology and **Radiation Oncology, Mayo Clinic, Scottsdale, AZ; ‖Carle Cancer Center Community Clinical Oncology Program, Urbana, IL; ¶Wichita Community Clinical Oncology Program, Wichita, KS; #Oncology and ‡‡Laboratory Medicine and Pathology, and Anatomic Pathology, Mayo Clinic, Rochester, MN; and ††Upstate Carolina CCOP, Spartanburg, SC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000383DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320011PMC
January 2015